MDxHealth specializes in advanced molecular diagnostics, particularly focusing on cancer detection and management. The company employs proprietary DNA-based technologies, notably its patented methylation-specific PCR (MSP) technology, to develop innovative diagnostic, prognostic, and predictive assays. These technologies are designed to enhance the accuracy of cancer diagnostics, particularly for prostate cancer, through products like Select mdx and Confirm mdx. These tests provide critical insights into the aggressiveness of prostate cancer, helping physicians make informed decisions regarding patient management and treatment options.

In addition to its diagnostic offerings, MDxHealth emphasizes collaboration with academic and commercial partners to drive research and development in the field of oncology. The company is committed to improving patient outcomes by providing accessible and affordable testing solutions that facilitate earlier detection of aggressive cancers. Through its clinical research network, MDxHealth aims to accelerate innovation and expand the availability of its molecular diagnostic solutions, ultimately enhancing the standard of care for patients with urologic diseases.

United States

Mdxhealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

MDxHealth

Company Details